NCT06140186View on ClinicalTrials.gov

Efficacy and Safety of Timolol for TKI Induced Paronychia

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

March 31, 2024

Conditions
Paronychia
Interventions
DRUG

Topical Timolol

Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.

DRUG

Betamethasone Valerate

Betamethasone valerate 0.1% cream application twice daily

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Queen Mary Hospital, Hong Kong

OTHER